NCT01502735View on ClinicalTrials.gov

Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Dengue Fever
Interventions
BIOLOGICAL

DENV-1 PIV, 2.5 µg

2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)

BIOLOGICAL

DENV-1 PIV, 5 µg

5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)

Trial Locations (1)

20910

WRAIR, Clinical Trials Center (CTC), Silver Spring

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT01502735 - Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease | Biotech Hunter | Biotech Hunter